

Rossella Elisei

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4949400/rossella-elisei-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

330
papers

21,517
citations

69
h-index

142
g-index

354
ext. papers

25,082
ext. citations

5.3
avg, IF

6.4
L-index

#	Paper	IF	Citations
330	European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. <i>European Journal of Endocrinology</i> , 2006 , 154, 787-803	6.5	1487
329	Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. <i>Thyroid</i> , 2015 , 25, 567-610	6.2	1191
328	Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 621-30	59.2	1078
327	Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 134-41	2.2	1000
326	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2014 , 384, 319-28	4.0	933
325	Cabozantinib in progressive medullary thyroid cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3639-46	2.2	762
324	Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 1493-501	27.4	605
323	BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 3943-9	5.6	416
322	Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 682-7	5.6	395
321	Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 163-8	5.6	389
320	Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 42-50	2.2	345
319	Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 926-32	5.6	337
318	Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 4085-90	5.6	329
317	Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 3668-73	5.6	319
316	Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3794-801	2.2	293
315	BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2414-20	5.6	235
314	Diagnostic ¹³¹ -iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 1499-501	5.6	223

313	Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. <i>Nature Reviews Endocrinology</i> , 2017 , 13, 644-660	15.2	208
312	RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 4725-9	5.6	203
311	Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 4092-7	5.6	194
310	RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 3211-6	5.6	192
309	Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. <i>Endocrine-Related Cancer</i> , 2006 , 13, 455-64	5.7	184
308	Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994 , 78, 826-9	5.6	184
307	The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 4390-8	5.6	175
306	A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. <i>Nature Reviews Endocrinology</i> , 2016 , 12, 192-202	15.2	173
305	Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of its completeness. <i>Surgery</i> , 2002 , 132, 1070-3; discussion 1073-4	3.6	170
304	Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992 , 74, 1401-4	5.6	170
303	Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 1316-24	5.6	167
302	Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 1516-27	5.6	167
301	RET/PTC Rearrangements in Thyroid Nodules: Studies in Irradiated and Not Irradiated, Malignant and Benign Thyroid Lesions in Children and Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 3211-3216	5.6	164
300	Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. <i>Endocrine-Related Cancer</i> , 2009 , 16, 1251-60	5.7	163
299	Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. <i>Journal of Nuclear Medicine</i> , 1987 , 28, 1888-91	8.9	159
298	Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 124-7	5.6	155
297	A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 44-53	12.9	152
296	Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 4063-8	5.6	145

295	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 264-74	5.6	144
294	Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 5686-90	5.6	142
293	Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 4197-205	5.6	139
292	N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. <i>Thyroid</i> , 2000 , 10, 19-23	6.2	136
291	A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. <i>Cancer</i> , 2015 , 121, 2749-56	6.4	130
290	Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. <i>Thyroid</i> , 2013 , 23, 50-7	6.2	126
289	Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996 , 81, 1619-22	5.6	122
288	Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. <i>Thyroid</i> , 2013 , 23, 1211-25	6.2	120
287	BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2008 , 15, 511-20	5.7	120
286	Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. <i>Endocrine-Related Cancer</i> , 2016 , 23, R185-205	5.7	119
285	Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. <i>Thyroid</i> , 2001 , 11, 877-81	6.2	118
284	Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. <i>European Journal of Endocrinology</i> , 1988 , 119, 373-80	6.5	112
283	Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. <i>Thyroid</i> , 2014 , 24, 232-40	6.2	108
282	Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. <i>Annals of Oncology</i> , 2017 , 28, 2813-2819	10.3	101
281	RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. <i>Frontiers in Endocrinology</i> , 2012 , 3, 54	5.7	99
280	Thyroid carcinoma in thyrotoxic patients treated by surgery. <i>Journal of Endocrinological Investigation</i> , 1988 , 11, 107-12	5.2	99
279	RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 3579-84	5.6	97
278	The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 426-35	5.6	96

277	Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. <i>Journal of Endocrinological Investigation</i> , 2018 , 41, 849-876	5.2	95
276	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. <i>European Journal of Endocrinology</i> , 2010 , 163, 301-8	6.5	95
275	2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer. <i>European Thyroid Journal</i> , 2019 , 8, 227-245	4.2	90
274	Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. <i>American Journal of Pathology</i> , 2002 , 160, 247-54	5.8	89
273	RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). <i>Clinical Endocrinology</i> , 2011 , 74, 241-7	3.4	82
272	The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 3511-6	5.6	82
271	Combined clinical, thyroid ultrasound and cytological features help to predict thyroid malignancy in follicular and Hupsilonnrthle cell thyroid lesions: results from a series of 505 consecutive patients. <i>Clinical Endocrinology</i> , 2007 , 66, 13-20	3.4	82
270	Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 4160-5	5.6	80
269	MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	78
268	MON-486 Polygenic Susceptibility to Papillary Thyroid Cancer in Italian Subjects. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	78
267	Detection of thyroid-stimulating antibody using Chinese hamster ovary cells transfected with cloned human thyrotropin receptor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993 , 76, 499-503	5.6	76
266	Targeted Therapy in Thyroid Cancer: State of the Art. <i>Clinical Oncology</i> , 2017 , 29, 316-324	2.8	74
265	Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 1618-22	5.6	73
264	Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens. <i>American Journal of Clinical Pathology</i> , 1991 , 95, 300-8	1.9	73
263	Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. <i>European Journal of Endocrinology</i> , 2014 , 171, R33-46	6.5	72
262	A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. <i>Thyroid</i> , 2009 , 19, 837-42	6.2	71
261	Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies. <i>Thyroid</i> , 2014 , 24, 966-74	6.2	69
260	Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 4171-9	5.6	69

259	Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. <i>Future Oncology</i> , 2013 , 9, 1083-92	3.6	68
258	Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 438-445	2.2	68
257	Anaplastic thyroid cancer: prevalence, diagnosis and treatment. <i>Minerva Endocrinologica</i> , 2008 , 33, 341-57	5.9	68
256	2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. <i>European Thyroid Journal</i> , 2013 , 1, 216-31	4.2	66
255	Genome-wide association study on differentiated thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E1674-81	5.6	64
254	Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. <i>Surgery</i> , 1995 , 118, 1031-5	3.6	63
253	Advances in the follow-up of differentiated or medullary thyroid cancer. <i>Nature Reviews Endocrinology</i> , 2012 , 8, 466-75	15.2	62
252	Routine serum calcitonin measurement in the evaluation of thyroid nodules. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008 , 22, 941-53	6.5	62
251	Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma. <i>Thyroid</i> , 2007 , 17, 389-93	6.2	62
250	Modifications in the papillary thyroid cancer gene profile over the last 15 years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, E1758-65	5.6	59
249	Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. <i>Cancer</i> , 1998 , 83, 2185-2193	6.4	59
248	European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. <i>Thyroid</i> , 2019 , 29, 7-26	6.2	59
247	Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. <i>Cancer</i> , 2016 , 122, 3856-3864	6.4	58
246	Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. <i>Thyroid</i> , 2007 , 17, 381-8	6.2	58
245	Involvement of protein kinase Cepsilon (PKCepsilon) in thyroid cell death. A truncated chimeric PKCepsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis. <i>Journal of Biological Chemistry</i> , 1999 , 274, 23414-25	5.4	57
244	Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. <i>Mutation Research - Reviews in Mutation Research</i> , 2013 , 752, 36-44	7	56
243	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 3241-3250	5.6	55
242	Genetic and clinical features of multiple endocrine neoplasia types 1 and 2. <i>Journal of Oncology</i> , 2012 , 2012, 705036	4.5	55

241	Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 748-54	5.6	55
240	A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).. <i>Journal of Clinical Oncology</i> , 2011 , 29, 5503-5503	2.2	55
239	Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 5823-7	5.6	54
238	An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5508-5508	2.2	54
237	Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 213-220	18.1	52
236	Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994 , 78, 867-71	5.6	50
235	Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. <i>Thyroid</i> , 2012 , 22, 476-81	6.2	49
234	In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2011 , 18, 603-12	5.7	49
233	Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. <i>Thyroid</i> , 2004 , 14, 946-52	6.2	49
232	Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing. <i>iScience</i> , 2019 , 20, 324-336	6.1	48
231	Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. <i>European Journal of Cancer</i> , 2019 , 118, 35-40	7.5	48
230	Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ^{131}I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 89, 2682-700	5.6	48
229	Video-assisted central compartment lymphadenectomy in a patient with a positive RET oncogene: initial experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2007 , 21, 120-3	5.2	48
228	Conditional apoptosis induced by oncogenic ras in thyroid cells. <i>Molecular Endocrinology</i> , 2000 , 14, 1725-38		48
227	Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. <i>Molecular and Cellular Endocrinology</i> , 2008 , 291, 57-62	4.4	47
226	Acute exogenous TSH administration stimulates leptin secretion in vivo. <i>European Journal of Endocrinology</i> , 2010 , 163, 63-7	6.5	46
225	Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2007 , 14, 1099-105	5.7	46
224	Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 33-9	5.6	45

223	Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. <i>Thyroid</i> , 2003 , 13, 765-70	6.2	45
222	Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994 , 78, 867-871	5.6	45
221	Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	43
220	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 362-370	9.7	42
219	Somatostatin in medullary thyroid cancer. In vitro and in vivo studies. <i>Cancer</i> , 1989 , 63, 1189-95	6.4	42
218	Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?. <i>Clinical Endocrinology</i> , 2015 , 82, 892-9	3.4	41
217	Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1137-47	3.5	41
216	Measurement of cAMP accumulation in Chinese hamster ovary cells transfected with the recombinant human TSH receptor (CHO-R): a new bioassay for human thyrotropin. <i>Journal of Endocrinological Investigation</i> , 1993 , 16, 511-9	5.2	40
215	Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. <i>European Journal of Cancer</i> , 2017 , 75, 213-221	7.5	39
214	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4-4	2.2	39
213	Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 4413-4420	5.6	38
212	RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2001 , 145, 599-604	6.5	38
211	New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double mutations. <i>Journal of Medical Genetics</i> , 2016 , 53, 729-734	5.8	38
210	BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2787-2795	2.2	38
209	Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. <i>Surgery</i> , 2012 , 152, 1078-87	3.6	37
208	Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2729-36	5.6	37
207	Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying the RET/PTC1 rearrangement. <i>International Journal of Cancer</i> , 2002 , 97, 608-14	7.5	37
206	All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 2403-11	5.6	37

205	Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E2084-92	5.6	35
204	Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid. <i>Molecular and Cellular Endocrinology</i> , 2009 , 307, 142-8	4.4	35
203	Identification of rapid turnover transcripts overexpressed in thyroid tumors and thyroid cancer cell lines: use of a targeted differential RNA display method to select for mRNA subsets. <i>Nucleic Acids Research</i> , 1997 , 25, 3823-31	20.1	35
202	Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 2389-95	5.6	34
201	Lack of evidence supporting the presence of mRNA for the thyrotropin receptor in extra-ocular muscle. <i>Journal of Endocrinological Investigation</i> , 1993 , 16, 329-32	5.2	32
200	Management of Medullary Thyroid Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019 , 48, 285-301	5.5	32
199	Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer. <i>European Journal of Cancer</i> , 1994 , 30A, 171-4	7.5	30
198	Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer. <i>OncoTargets and Therapy</i> , 2016 , 9, 6467-6477	4.4	29
197	New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 3-9	5.2	29
196	Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters. <i>Thyroid</i> , 2011 , 21, 1209-15	6.2	28
195	Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 893-902	5.6	27
194	Evidences that the polymorphism Pro-282-Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma. <i>International Journal of Cancer</i> , 2011 , 129, 2816-24	7.5	26
193	Simian virus 40-like sequences from early and late regions in human thyroid tumors of different histotypes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 892-9	5.6	26
192	Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology. <i>Journal of Endocrinological Investigation</i> , 2016 , 39, 341-7	5.2	25
191	Identification of Two Distinct Molecular Subtypes of Non-Invasive Follicular Neoplasm with Papillary-Like Nuclear Features by Digital RNA Counting. <i>Thyroid</i> , 2017 , 27, 1267-1276	6.2	25
190	CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2011 , 164, 397-404	6.5	25
189	RET proto-oncogene mutations in thyroid carcinomas: clinical relevance. <i>Journal of Endocrinological Investigation</i> , 2000 , 23, 328-38	5.2	25
188	Studies with recombinant autoepitopes of thyroid peroxidase: evidence suggesting an epitope shared between the thyroid and the gastric parietal cell. <i>Autoimmunity</i> , 1990 , 8, 65-70	3	25

187	Video assisted prophylactic thyroidectomy and central compartment nodes clearance in two RET gene mutation adult carriers. <i>Journal of Endocrinological Investigation</i> , 2004 , 27, 557-61	5.2	24
186	Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 4047-50	5.6	24
185	BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. <i>European Journal of Cancer</i> , 2020 , 124, 161-169	7.5	24
184	Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer. <i>European Journal of Endocrinology</i> , 2015 , 173, 297-304	6.5	23
183	Interventional bronchoscopy in the treatment of tracheal obstruction secondary to advanced thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 2006 , 29, 131-5	5.2	23
182	Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017 , 31, 319-334	6.5	22
181	Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations. <i>Genes</i> , 2019 , 10,	4.2	22
180	Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk. <i>Scientific Reports</i> , 2015 , 5, 8922	4.9	21
179	T cell responses to orbital antigens in thyroid-associated ophthalmopathy. <i>Clinical and Experimental Immunology</i> , 1994 , 96, 329-34	6.2	21
178	Demonstration of the existence of the alternatively spliced form of thyroid peroxidase in normal thyroid. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 72, 700-2	5.6	21
177	Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without I Ablation. <i>Thyroid</i> , 2018 , 28, 871-879	6.2	21
176	Medullary thyroid cancer secreting carbohydrate antigen 19-9 (Ca 19-9): a fatal case report. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 3550-4	5.6	20
175	A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5591-5591	2.2	20
174	Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6012-6012	2.2	20
173	Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: european comments to the guidelines of the American Thyroid Association. <i>Thyroid Research</i> , 2013 , 6 Suppl 1, S2	2.4	19
172	Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein. <i>Clinical Endocrinology</i> , 2003 , 59, 500-6	3.4	19
171	RET/PTC3 rearrangement and thyroid differentiation gene analysis in a struma ovarii fortuitously revealed by elevated serum thyroglobulin concentration. <i>Thyroid</i> , 2005 , 15, 1355-61	6.2	19
170	A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 5502-5502	2.2	19

169	Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response. <i>Endocrine-Related Cancer</i> , 2020 , 27, 97-110	5.7	19
168	Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2773-2781	2.2	18
167	Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity. <i>Human Pathology</i> , 2007 , 38, 1482-8	3.7	18
166	Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland. <i>Journal of Endocrinological Investigation</i> , 2017 , 40, 55-62	5.2	17
165	A Comprehensive Meta-analysis of Case-Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 700-13	4	16
164	A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA6008-LBA6008	2.2	16
163	RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases. <i>Oncotarget</i> , 2018 , 9, 9875-9884	3.3	16
162	Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma. <i>Head and Neck</i> , 2018 , 40, 1752-1758	4.2	15
161	FoxP3 expression in papillary thyroid carcinoma: a possible resistance biomarker to iodine 131 treatment. <i>Thyroid</i> , 2014 , 24, 339-46	6.2	15
160	Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. <i>Molecular and Cellular Endocrinology</i> , 2012 , 348, 176-82	4.4	15
159	Role of RET codonic mutations in the surgical management of medullary thyroid carcinoma in pediatric age multiple endocrine neoplasm type 2 syndromes. <i>Journal of Pediatric Surgery</i> , 2010 , 45, 1610-6	3.6	15
158	New breakpoints in both the H4 and RET genes create a variant of PTC-1 in a post-Chernobyl papillary thyroid carcinoma. <i>Clinical Endocrinology</i> , 2000 , 53, 131-6	3.4	15
157	Muscle autoantigens in thyroid associated ophthalmopathy: the limits of molecular genetics. <i>Journal of Endocrinological Investigation</i> , 1993 , 16, 533-40	5.2	15
156	Runs of homozygosity and inbreeding in thyroid cancer. <i>BMC Cancer</i> , 2016 , 16, 227	4.8	15
155	Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer. <i>Thyroid</i> , 2021 , 31, 224-232	6.2	15
154	How to manage patients with differentiated thyroid cancer and a rising serum thyroglobulin level. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014 , 43, 331-44	5.5	14
153	Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapeutic effect of vinorelbine in the medullary thyroid cancer TT cell line. <i>Molecular and Cellular Endocrinology</i> , 2012 , 355, 41-8	4.4	14
152	TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. <i>International Journal of Cancer</i> , 2013 , 133, 2843-51	7.5	14

151	Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment. <i>Journal of Endocrinological Investigation</i> , 2008 , 31, 724-30	5.2	14
150	Thyroid papillary carcinoma: preliminary evidence for a germ-line single nucleotide polymorphism in the Fas gene. <i>Journal of Endocrinology</i> , 2004 , 182, 479-84	4.7	14
149	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4-4	2.2	14
148	Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience. <i>Oncology Letters</i> , 2018 , 15, 9174-9182	2.6	14
147	Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. <i>Cancer</i> , 1998 , 83, 2185-93	6.4	14
146	Potential Impact of BMI on the Aggressiveness of Presentation and Clinical Outcome of Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	13
145	Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	13
144	A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	13
143	Effects of radioiodine treatment for differentiated thyroid cancer on testis function. <i>Clinical Endocrinology</i> , 2015 , 82, 295-9	3.4	12
142	mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study. <i>Journal of Endocrinological Investigation</i> , 2018 , 41, 1389-1399	5.2	12
141	Expression of cAMP response element-binding protein and sodium iodide symporter in benign non-functioning and malignant thyroid tumours. <i>European Journal of Endocrinology</i> , 2003 , 148, 579-86	6.5	12
140	A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4810-6	5.6	12
139	Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2019 , 26, 241-250	5.7	12
138	somatic mutations strongly impair miRNA processing even in benign thyroid lesions. <i>Oncotarget</i> , 2019 , 10, 1785-1797	3.3	12
137	Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 2520-2526	5.6	11
136	Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 4387-95	5.6	11
135	Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6060-6060	2.2	11
134	Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer. <i>European Thyroid Journal</i> , 2016 , 5, 187-194	4.2	10

133	Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 109-116	5.2	10
132	Rare diseases in clinical endocrinology: a taxonomic classification system. <i>Journal of Endocrinological Investigation</i> , 2015 , 38, 193-259	5.2	9
131	Medullary thyroid carcinoma in children. <i>Endocrine Development</i> , 2014 , 26, 202-13		9
130	Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 2001 , 24, 445-7	5.2	8
129	Post-surgical follow-up of differentiated thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 1995 , 18, 165-6	5.2	8
128	Expression of calcitonin gene-related peptide in medullary thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 1992 , 15, 539-42	5.2	8
127	BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 3228-3238	5.6	8
126	Proteinuria is a late-onset adverse event in patients treated with cabozantinib. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 95-103	5.2	8
125	Ultrasound features and risk stratification systems to identify medullary thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2021 , 185, 193-200	6.5	8
124	Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response. <i>Endocrine-Related Cancer</i> , 2020 , 27, 97-110	5.7	8
123	Risk of differentiated thyroid carcinoma and polymorphisms within the susceptibility cancer region 8q24. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 2121-5	4	7
122	Role of YAP-1 in Thyroid Tumor Progression and Outcome. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017 , 25, 581-585	1.9	7
121	Thyroid nodule and differentiated thyroid cancer management in pregnancy. An Italian Association of Clinical Endocrinologists (AME) and Italian Thyroid Association (AIT) Joint Statement for Clinical Practice. <i>Journal of Endocrinological Investigation</i> , 2010 , 33, 579-86	5.2	7
120	Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6048-6048	2.2	7
119	Surgical Management of Medullary Thyroid Carcinoma in Pediatric Age. <i>Current Pediatric Reviews</i> , 2016 , 12, 280-285	2.8	7
118	Follicular-derived neoplasms: morphometric and genetic differences. <i>Journal of Endocrinological Investigation</i> , 2013 , 36, 1055-61	5.2	7
117	Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma. <i>Annales DiEndocrinologie</i> , 2019 , 80, 187-190	1.7	6
116	Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up. <i>Endocrine</i> , 2020 , 68, 607-616	4	6

115	Epidemiology of Simultaneous Medullary and Papillary Thyroid Carcinomas (MTC/PTC): An Italian Multicenter Study. <i>Cancers</i> , 2019 , 11,	6.6	6
114	Location of functioning metastases from differentiated thyroid carcinoma by simultaneous double isotope acquisition of I-131 whole body scan and bone scan. <i>Journal of Endocrinological Investigation</i> , 2004 , 27, 866-9	5.2	6
113	Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6061-6061	2.2	6
112	A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA6008-LBA6008	2.2	6
111	Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. <i>Thyroid</i> , 2021 , 31, 1226-1234	6.2	6
110	Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism. <i>Seminars in Cancer Biology</i> , 2021 ,	12.7	6
109	Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selipercatinib: a case report. <i>Annals of Oncology</i> , 2021 , 32, 1447-1449	10.3	6
108	Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence?. <i>International Journal of Cancer</i> , 2020 , 147, 2838-2846	7.5	6
107	Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey. <i>Frontiers in Endocrinology</i> , 2020 , 11, 381	5.7	5
106	Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma. <i>Archives of Toxicology</i> , 2016 , 90, 3099-3109	5.8	5
105	Incidental versus clinically evident thyroid cancer: a 5-year follow-up study. <i>Head and Neck</i> , 2013 , 35, 408-12	4.2	5
104	Detection of metastases from differentiated thyroid cancer by different imaging techniques (neck ultrasound, computed tomography and [18F]-FDG positron emission tomography) in patients with negative post-therapeutic ¹³¹ I whole-body scan and detectable serum thyroglobulin levels. <i>Journal of Endocrinological Investigation</i> , 2014 , 27, 247-50	5.2	5
103	2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?. <i>European Thyroid Journal</i> , 2022 , 11,	4.2	5
102	Molecular Alterations in Relation to Histopathological Characteristics in a Large Series of Pediatric Papillary Thyroid Carcinoma from a Single Institution. <i>Cancers</i> , 2021 , 13,	6.6	5
101	Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma. <i>DNA Repair</i> , 2016 , 41, 27-31	4.3	5
100	Less than 2% of the Low- and Intermediate-Risk Differentiated Thyroid Cancers Show Distant Metastases at Post-Ablation Whole-Body Scan. <i>European Thyroid Journal</i> , 2019 , 8, 90-95	4.2	5
99	DELAYED 131-I FIRST TREATMENT AFTER SURGERY HAS NO IMPACT ON THE MEDIAN TERM OUTCOME OF PATIENTS WITH INTERMEDIATE RISK DIFFERENTIATED THYROID CANCER. <i>Endocrine Practice</i> , 2020 , 26, 58-71	3.2	5
98	Multiethnic genome-wide association study of differentiated thyroid cancer in the EPITHYR consortium. <i>International Journal of Cancer</i> , 2021 , 148, 2935-2946	7.5	5

97	Thyroid cancer and COVID-19: experience at one single thyroid disease referral center. <i>Endocrine</i> , 2021 , 72, 332-339	4	5
96	Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 2139-2151	5.2	5
95	Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients. <i>Journal of Endocrinological Investigation</i> , 2018 , 41, 357-361	5.2	4
94	The polymorphism rs2480258 within CYP2E1 is associated with different rates of acrylamide metabolism in vivo in humans. <i>Archives of Toxicology</i> , 2018 , 92, 2137-2140	5.8	4
93	Inherited variants in genes somatically mutated in thyroid cancer. <i>PLoS ONE</i> , 2017 , 12, e0174995	3.7	4
92	Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma. <i>Cancers</i> , 2020 , 13,	6.6	4
91	Ca19.9 Positivity and Doubling Time Are Prognostic Factors of Mortality in Patients with Advanced Medullary Thyroid Cancer with No Evidence of Structural Disease Progression According to Response Evaluation Criteria in Solid Tumors. <i>Thyroid</i> , 2021 , 31, 1050-1055	6.2	4
90	Management and follow-up of differentiated thyroid cancer not submitted to radioiodine treatment: a systematic review. <i>Minerva Endocrinologica</i> , 2020 , 45, 306-317	1.9	4
89	Incidental occurrence of metastatic medullary thyroid carcinoma in a patient with multiple endocrine neoplasia type 1 carrying germline MEN1 and somatic RET mutations. <i>Journal of Surgical Oncology</i> , 2017 , 116, 1197-1199	2.8	3
88	Medullary Thyroid Cancer: Diagnosis and Management 2006 , 255-279		3
87	Transfection with the cDNA of the human thyrotropin receptor of a poorly differentiated rat thyroid cell line (FRT). <i>Journal of Endocrinological Investigation</i> , 1996 , 19, 230-5	5.2	3
86	Efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6013-6013	2.2	3
85	Role of Prophylactic Central Compartment Lymph Node Dissection on the Outcome Of Patients With Papillary Thyroid Carcinoma and Synchronous Ipsilateral Cervical Lymph Node Metastases. <i>Endocrine Practice</i> , 2020 , 26, 807-817	3.2	3
84	Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e4072-e4083	5.6	3
83	Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 2557-2566	5.2	3
82	The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy. <i>Frontiers in Oncology</i> , 2019 , 9, 1390	5.3	3
81	Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment. <i>Frontiers in Endocrinology</i> , 2018 , 9, 590	5.7	3
80	MANAGEMENT OF ENDOCRINE DISEASE: Papillary thyroid microcarcinoma: toward an active surveillance strategy. <i>European Journal of Endocrinology</i> , 2021 , 185, R23-R34	6.5	3

79	Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas 1998 , 83, 2185		3
78	Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer. <i>Case Reports in Endocrinology</i> , 2019 , 2019, 6831237	1.2	2
77	Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	2
76	Clinical Management of a Patient with a Locally Recurrent Medullary Thyroid Cancer and Asymptomatic Slowly Progressing Distant Metastases 2016 , 347-354		2
75	Patients with Indeterminate Thyroid Nodules at Cytology and Cancer at Histology Have a More Favorable Outcome Compared with Patients with Suspicious or Malignant Cytology. <i>Thyroid</i> , 2018 , 28, 1318-1324	6.2	2
74	KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 3091-3096	5.6	2
73	Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6014-6014	2.2	2
72	Analysis of tumor growth rate for radioiodine (RAI)-refractory differentiated thyroid cancer patients receiving placebo and/or sorafenib in the phase III DECISION study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6015-6015	2.2	2
71	Calcitonin receptor expression in medullary thyroid carcinoma. <i>PeerJ</i> , 2017 , 5, e3778	3.1	2
70	Thyroid Cancer in Ukraine After the Chernobyl Accident: Incidence, Pathology, Treatment, and Molecular Biology 2009 , 305-316		2
69	1927TiP LIBRETTO-531: Selpercatinib in patients with treatment (Tx)-naïve RET-mutant medullary thyroid cancer (MTC). <i>Annals of Oncology</i> , 2020 , 31, S1091	10.3	2
68	Poorly Differentiated and Anaplastic Thyroid Cancer: Insights into Genomics, Microenvironment and New Drugs. <i>Cancers</i> , 2021 , 13,	6.6	2
67	Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 163, 103366	7	2
66	Reply to the Letter to the Editor by Sollini M et al. <i>Journal of Endocrinological Investigation</i> , 2016 , 39, 487-8	5.2	2
65	First report of benign track seeding after robot-assisted transaxillary thyroid surgery. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2021 , 42, 102811	2.8	2
64	Using The Cancer Genome Atlas data to refine the 8th edition of the American Joint Committee on Cancer staging for papillary thyroid carcinoma. <i>Endocrine</i> , 2021 , 72, 140-146	4	2
63	Thyroid Carcinoma 2018 , 573-585		2
62	Biology and clinical application of the NIS gene. <i>Tumori</i> , 2003 , 89, 523-8	1.7	2

61	Response to Letter: "Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restrartification and Decision to Perform 131I Ablation". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1785-1786	5.6	1
60	A Comparison of the ATA, NCCN, ETA, and BTA Guidelines for the Management of Medullary Thyroid Cancer 2016 , 899-910		1
59	SP134PROTEINURIA IS A LATE ONSET ADVERSE EVENT IN PATIENTS TREATED WITH CABOZANTINIB: A SINGLE CENTER EXPERIENCE. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, i388-i389	4.3	1
58	Comunicare con la persona con cancro della tiroide in progressione. <i>L Endocrinologo</i> , 2017 , 18, 224-230	0	1
57	Cabozantinib: an orphan drug for thyroid cancer. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 1469-1477	1.1	1
56	Clinical case seminar in pediatric thyroid disease. <i>Endocrine Development</i> , 2014 , 26, 214-44		1
55	Ethics in Robotic Surgery and Telemedicine 2010 , 457-465		1
54	Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 2004 , 27, 636-42	5.2	1
53	Firm mass in thyroid of an elderly patient: not always cancer. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2020 , 2020,	1.4	1
52	Diagnostic Applications of Nuclear Medicine: Thyroid Tumors 2017 , 545-583		1
51	Diagnostic Applications of Nuclear Medicine: Thyroid Tumors 2016 , 1-40		1
50	[18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 2355-2366	5.6	1
49	Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade. <i>Journal of the Endocrine Society</i> , 2021 , 5, bvab093	0.4	1
48	Tall cell percentage alone in PTC without aggressive features should not guide patients' clinical management. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e4109-e4117	5.6	1
47	Pro64His (rs4644) Polymorphism Within Galectin-3 Is a Risk Factor of Differentiated Thyroid Carcinoma and Affects the Transcriptome of Thyrocytes Engineered via CRISPR/Cas9 System. <i>Thyroid</i> , 2021 , 31, 1056-1066	6.2	1
46	Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase?. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
45	Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer. <i>European Thyroid Journal</i> , 2021 , 10, 399-407	4.2	1
44	Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 864253	5.7	1

43	Clinical-Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 842424	5.7	1
42	Polymorphisms Within the Proto-Oncogene and Risk of Sporadic Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2020 , 30, 1579-1588	6.2	0
41	Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas. <i>Endocrine</i> , 2019 , 65, 623-629	4	0
40	Radionuclide Therapy of Thyroid Tumors 2017 , 1197-1241		0
39	A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New Germline Deletion. <i>Case Reports in Endocrinology</i> , 2020 , 2020, 4147097	1.2	0
38	Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo. <i>Thyroid</i> , 2021 , 31, 330-331	6.2	0
37	RET mutated C-cells proliferate more rapidly than non-mutated neoplastic cells. <i>Endocrine Connections</i> , 2021 , 10, 124-130	3.5	0
36	Clinical impact of molecular techniques for the presurgical diagnosis of differentiated thyroid cancer diagnosis. <i>Expert Review of Endocrinology and Metabolism</i> , 2017 , 12, 207-214	4.1	
35	È ancora indicazione alla terapia radioablativa con 131-I nel carcinoma tiroideo differenziato a basso rischio?. <i>L Endocrinologo</i> , 2017 , 18, 51-53		0
34	Medullary Thyroid Cancer 2019 , 673-691		
33	Letter to the Editor-ResponseResponse to Letter to the Editor: "Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	
32	Eterogeneità genetica del carcinoma tiroideo. <i>L Endocrinologo</i> , 2020 , 21, 48-50		0
31	Alterazioni genomiche e trascrittomiche che caratterizzano il carcinoma scarsamente differenziato e anaplastico della tiroide. <i>L Endocrinologo</i> , 2016 , 17, 176-177		0
30	Influenza dell'avanzare dell'età sulla formazione dei noduli tiroidei, sull'evoluzione multinodulare e sul rischio neoplastico. <i>L Endocrinologo</i> , 2016 , 17, 62-63		0
29	A Patient with an Advanced Medullary Thyroid Cancer and Progressive, Symptomatic Distant Metastases: When to Start Systemic Therapy 2016 , 355-363		
28	Il carcinoma tiroideo: nuove prospettive terapeutiche. <i>L Endocrinologo</i> , 2014 , 15, 28-35		0
27	Thyroid and Parathyroid Tumors 2013 , 297-361		
26	A patient with MEN1 and end-stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation. <i>Molecular and Clinical Oncology</i> , 2018 , 8, 449-452	1.6	

- 25 Impatto dell'analisi di sequenza multigenica avanzata Thyroseq sulla diagnosi di cancro nei noduli tiroidei con atipie di incerto significato e/o lesioni follicolari a citologia indeterminata. *L Endocrinologo*, **2015**, 16, 237-238 ○
- 24 Nuove indicazioni all'impiego del TSH umano ricombinante (rhTSH) e basse attività di ^{131}I nella radioablazione del residuo tiroideo post-chirurgico. *L Endocrinologo*, **2013**, 14, 255-260 ○
- 23 Correlazione genotipo-fenotipo nelle MEN 2: stato dell'arte dopo 15 anni di conoscenze. *L Endocrinologo*, **2010**, 11, 94-101 ○
- 22 Reply to J.-F. Chatal et al. *Journal of Clinical Oncology*, **2012**, 30, 2166-2167 2.2
- 21 Consenso europeo para el tratamiento de los pacientes con carcinoma tiroideo diferenciado del epitelio folicular. *Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion*, **2007**, 54, 390.e1-390.e16
- 20 Tiroidectomia profilattica nelle neoplasie endocrine multiple di tipo 2A. *L Endocrinologo*, **2005**, 6, 200-204 ○
- 19 Diagnosi genetica del carcinoma midollare della tiroide: implicazioni diagnostiche e terapeutiche. *L Endocrinologo*, **2004**, 5, 39-46 ○
- 18 Nuovi farmaci inibitori selettivi di RET (selpercatinib e pralsetinib) nei pazienti con carcinoma midollare della tiroide avanzato. *L Endocrinologo*, 1 ○
- 17 Carcinoma differenziato della tiroide radioiodio-refrattario in progressione trattato con lenvatinib. *L Endocrinologo*, **2021**, 22, 570 ○
- 16 La gestione multidisciplinare delle metastasi ossee nel carcinoma tiroideo. *L Endocrinologo*, **2021**, 22, 497 ○
- 15 Authors' Response: Should Serum Calcitonin Be Routinely Measured in Patients with Thyroid Nodules? Will the Law Answer before Endocrinologists Do?. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 4770-4770 5.6
- 14 Medullary Carcinoma. *Endocrinology*, **2018**, 1-39 0.1
- 13 Esami diagnostici nel sospetto di carcinoma midollare della tiroide. *L Endocrinologo*, **2021**, 22, 454 ○
- 12 A Patient with an Advanced Medullary Thyroid Cancer and Progressive, Symptomatic Distant Metastases: When to Start Systemic Therapy **2021**, 337-346
- 11 Clinical Management of a Patient with a Locally Recurrent Medullary Thyroid Cancer and Asymptomatic Slowly Progressing Distant Metastases **2021**, 327-335
- 10 Radionuclide Therapy of Thyroid Tumors **2016**, 1-47
- 9 Carcinoma della tiroide **2011**, 403-420
- 8 Qualità della vita nei pazienti con microcarcinoma papillare della tiroide in funzione del trattamento: tiroidectomia totale con o senza terapia radiometabolica ablativa. *L Endocrinologo*, **2020**, 21, 397-398 ○

- 7 I tempi della tiroidectomia nella MEN2. *L Endocrinologo*, **2021**, 22, 59-61 ○
- 6 Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato. *L Endocrinologo*, **2016**, 17, 266-267 ○
- 5 Medullary Thyroid Cancer: Diagnosis and Non Surgical Management **2018**, 223-239
- 4 Medullary Carcinoma. *Endocrinology*, **2018**, 589-627 ○.1
- 3 Bilateral testicular metastases of MTC in an adult male with MEN2A syndrome: case report and review of literature.. *European Thyroid Journal*, **2022**, 4.2
- 2 Diagnostic Applications of Nuclear Medicine: Thyroid Tumors **2022**, 1-40
- 1 Radionuclide Therapy of Thyroid Tumors **2022**, 1-50